Identification of an HLA-A*0201 restricted Bcl2-derived epitope expressed on tumors

Cancer Letters

Volumn 251, Issue 1, 2007, Pages 86-95

  Wang, Mingjun ^a   Johansen, Britta ^a   Nissen, Mogens H ^a   Thorn, Mette ^b   Kløverpris, Henrik ^b   Fomsgaard, Anders ^b   Buus, Søren ^a   Claësson, Mogens H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

Bcl2 epitope; Cytotoxic T lymphocytes; HLA A*0201; Tumor

Indexed keywords

CASPASE 3; EPITOPE; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL X; TUMOR ANTIGEN; APOPTOSIS REGULATORY PROTEIN; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; OLIGOPEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BINDING AFFINITY; CANCER CELL CULTURE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL SURVIVAL; COLON CARCINOMA; CYTOTOXIC T LYMPHOCYTE; FIBROBLAST; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL STRAIN K 562; CHEMISTRY; CYTOTOXICITY; CYTOTOXICITY TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETICS; IMMUNOLOGY; MALE; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

MUS; MUS MUSCULUS;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HLA-A ANTIGENS; HUMANS; K562 CELLS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; OLIGOPEPTIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 34247147620     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.11.004     Document Type: Article

References (52)

1. Van den Eynde B.J., and Boon T. Tumor antigens recognized by T lymphocytes. Int. J. Clin. Lab. Res. 27 (1997) 81-86
2. Marchand M., van B.N., Weynants P., Brichard V., Dreno B., Tessier M.H., et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80 (1999) 219-230
3. Rosenberg S.A. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J. Natl. Cancer Inst. 88 (1996) 1635-1644
4. Albino A.P., Lloyd K.O., Houghton A.N., Oettgen H.F., and Old L.J. Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. J. Exp. Med. 154 (1981) 1764-1778
5. Cormier J.N., Hijazi Y.M., Abati A., Fetsch P., Bettinotti M., Steinberg S.M., et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int. J. Cancer 75 (1998) 517-524
6. Berinstein N.L. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J. Clin. Oncol. 20 (2002) 2197-2207
7. Fong L., and Small E.J. Immunotherapy for prostate cancer. Semin. Oncol. 30 (2003) 649-658
8. Brossart P., Stuhler G., Flad T., Stevanovic S., Rammensee H.G., Kanz L., et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 58 (1998) 732-736
9. Brossart P., Heinrich K.S., Stuhler G., Behnke L., Reichardt V.L., Stevanovic S., et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93 (1999) 4309-4317
10. Zwaveling S., Van der Burg S.H., Menon A.G., Melief C.J., and Offringa R. Immunotherapy of cancer through targeting of the p53 tumor antigen. Arch. Immunol. Ther. Exp. (Warsz.) 50 (2002) 297-305
11. Vonderheide R.H., Hahn W.C., Schultze J.L., and Nadler L.M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10 (1999) 673-679
12. Campoli M., Chang C.C., and Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 20 Suppl. 4 (2002) A40-A45
13. Riker A., Cormier J., Panelli M., Kammula U., Wang E., Abati A., et al. Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126 (1999) 112-120
14. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3 (1997) 917-921
15. Findley H.W., Gu L., Yeager A.M., and Zhou M. Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 89 (1997) 2986-2993
16. Reed J.C., Miyashita T., Takayama S., Wang H.G., Sato T., Krajewski S., et al. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell Biochem. 60 (1996) 23-32
17. Weller M., Malipiero U., Aguzzi A., Reed J.C., and Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Invest. 95 (1995) 2633-2643
18. Lacasse E.C., Baird S., Korneluk R.G., and MacKenzie A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17 (1998) 3247-3259
19. Hu W., and Kavanagh J.J. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 4 (2003) 721-729
20. Berghella A.M., Pellegrini P., Contasta I., Del B.T., and Adorno D. Bcl-2 and drugs used in the treatment of cancer: new strategies of biotherapy which should not be underestimated. Cancer Biother. Radiopharm. 13 (1998) 225-237
21. Coultas L., and Strasser A. The role of the Bcl-2 protein family in cancer. Semin. Cancer Biol. 13 (2003) 115-123
22. Rudin C.M., Otterson G.A., Mauer A.M., Villalona-Calero M.A., Tomek R., Prange B., et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann. Oncol. 13 (2002) 539-545
23. Schimmer A.D., Munk-Pedersen I., Minden M.D., and Reed J.C. Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr. Treat. Options Oncol. 4 (2003) 211-218
24. Kusenda J. Bcl-2 family proteins and leukemia. Minireview. Neoplasma 45 (1998) 117-122
25. Reed J.C. Mechanisms of apoptosis avoidance in cancer. Curr. Opin. Oncol. 11 (1999) 68-75
26. Andersen M.H., Svane I.M., Kvistborg P., Nielsen O.J., Balslev E., Reker S., et al. Immunogenicity of Bcl-2 in patients with cancer. Blood 105 (2005) 728-734
27. Lauemoller S.L., Kesmir C., Corbet S.L., Fomsgaard A., Holm A., Claesson M.H., et al. Identifying cytotoxic T cell epitopes from genomic and proteomic information: the human MHC project. Rev. Immunogenet. 2 (2000) 477-491
28. Petersen T.R., Bregenholta S., Pedersen L.O., Nissen M.H., and Claesson M.H. Human p53(264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice. Cancer Lett. 137 (1999) 183-191
29. Nissen M.H., Thim L., and Christensen M. Purification and biochemical characterization of the complete structure of a proteolytically modified beta-2-microglobulin with biological activity. Eur. J. Biochem. 163 (1987) 21-28
30. Kaestel C.G., Madsen H.O., Prause J.U., Jorgensen A., Liang Y., la C.M., et al. Lack of FasL expression in cultured human retinal pigment epithelial cells. Exp. Clin. Immunogenet. 18 (2001) 34-41
31. Stryhn A., Pedersen L.O., Romme T., Holm C.B., Holm A., and Buus S. Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding. Eur. J. Immunol. 26 (1996) 1911-1918
32. Alexander J., Sidney J., Southwood S., Ruppert J., Oseroff C., Maewal A., et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1 (1994) 751-761
33. Buus S., Stryhn A., Winther K., Kirkby N., and Pedersen L.O. Receptor-ligand interactions measured by an improved spun column chromatography technique. A high efficiency and high throughput size separation method. Biochim. Biophys. Acta 1243 (1995) 453-460
34. Pedersen L.O., Stryhn A., Holter T.L., Etzerodt M., Gerwien J., Nissen M.H., et al. The interaction of beta 2-microglobulin (beta 2m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2m. Eur. J. Immunol. 25 (1995) 1609-1616
35. Wang M.J., Nissen M.H., Buus S., Ropke C., and Claesson M.H. Comparison of CTL reactivity in the spleen and draining lymph nodes after immunization with peptides pulsed on dendritic cells or mixed with Freund's incomplete adjuvant. Immunol. Lett. 90 (2003) 13-18
36. Taupin J.L., Tian Q., Kedersha N., Robertson M., and Anderson P. The RNA-binding protein TIAR is translocated from the nucleus to the cytoplasm during Fas-mediated apoptotic cell death. Proc. Natl. Acad. Sci. USA 92 (1995) 1629-1633
37. Kelliher M.A., Grimm S., Ishida Y., Kuo F., Stanger B.Z., and Leder P. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 8 (1998) 297-303
38. Grimm S., Stanger B.Z., and Leder P. RIP and FADD: two "death domain"-containing proteins can induce apoptosis by convergent, but dissociable, pathways. Proc. Natl. Acad. Sci. USA 93 (1996) 10923-10927
39. Hsu H., Huang J., Shu H.B., Baichwal V., and Goeddel D.V. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4 (1996) 387-396
40. Stanger B.Z., Leder P., Lee T.H., Kim E., and Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 81 (1995) 513-523
41. Takaoka A., Adachi M., Okuda H., Sato S., Yawata A., Hinoda Y., et al. Anti-cell death activity promotes pulmonary metastasis of melanoma cells. Oncogene 14 (1997) 2971-2977
42. Hao X.P., Ilyas M., and Talbot I.C. Expression of Bcl-2 and p53 in the colorectal adenoma-carcinoma sequence. Pathobiology 65 (1997) 140-145
43. Yang H.B., Chow N.H., Sheu B.S., Chan S.H., Chien C.H., and Su I.J. The role of bcl-2 in the progression of the colorectal adenoma-carcinoma sequence. Anticancer Res. 19 (1999) 727-730
44. Sette A., Vitiello A., Reherman B., Fowler P., Nayersina R., Kast W.M., et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153 (1994) 5586-5592
45. Andersen M.H., Pedersen L.O., Becker J.C., and Straten P.T. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 61 (2001) 869-872
46. Albert M.L., Sauter B., and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (1998) 86-89
47. Fonteneau J.F., Kavanagh D.G., Lirvall M., Sanders C., Cover T.L., Bhardwaj N., et al. Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells. Blood 102 (2003) 4448-4455
48. Joensuu H., Pylkkanen L., and Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol. 145 (1994) 1191-1198
49. Sjostrom J., Blomqvist C., von B.K., Bengtsson N.O., Mjaaland I., Malmstrom P., et al. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin. Cancer Res. 8 (2002) 811-816
50. Menendez P., Vargas A., Bueno C., Barrena S., Almeida J., De S.M., et al. Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation. Leukemia 18 (2004) 491-498
51. Grayson J.M., Zajac A.J., Altman J.D., and Ahmed R. Cutting edge: increased expression of Bcl-2 in antigen-specific memory CD8+ T cells. J. Immunol. 164 (2000) 3950-3954
52. Broome H.E., Dargan C.M., Krajewski S., and Reed J.C. Expression of Bcl-2, Bcl-x, and Bax after T cell activation and IL-2 withdrawal. J. Immunol. 155 (1995) 2311-2317